Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 25, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

April 1, 2028

Conditions
CAR T Cell TherapySystemic Lupus ErythematosusBCMA
Interventions
BIOLOGICAL

anti-BCMA/CD70-CAR-T cells

Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.

Trial Locations (1)

310052

RECRUITING

hildren's Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

Chongqing Precision Biotech Co., Ltd

INDUSTRY

lead

The Children's Hospital of Zhejiang University School of Medicine

OTHER